We use cookies to improve the performance of our site and optimize it for our users. Customize Cookie Preferences

Sign Up Today and Learn More About Laviana Pharma Stock

Invest in or calculate the value of your shares in Laviana Pharma or other pre-IPO companies through EquityZen's platform.

Get Started

Laviana Pharma Stock (LAPH)

Laviana Pharmatech specializes in providing process and manufacture outsourcing services for the pharmaceutical industry.

About Laviana Pharma Stock

Founded

2005

Industries

Software, Artificial Intelligence, Data and Analytics

Laviana Pharma Co., Ltd. founded in 2005 is a high-tech enterprise. It specializes in providing process and manufacture outsourcing services (CDMO) for the pharmaceutical industry. The main scope of services covers all chemistry-related aspects of process development and transformation for the innovative drug substances and products from laboratory scale to commercialized scale, including process research, process development, process optimization, pilot production and large-scale production of intermediates, API starting materials and API (active pharmaceutical ingredient) for pre-clinical, clinical trial materials and commercialized products. It also provides CMC services for IND and NDA submission of innovative developmental drug. It has three wholly-owned subsidiary, namely, Beijing laviana Pharmatech Co., Ltd., Laviana (Tianjin) Pharmatech Development Co., Ltd., and Laviana Corporation incorporated in United States.

Laviana Pharma Management

Leadership team at Laviana Pharma

CFO

Ling Lu

CSO

Guang Yang

Locked Features

Join now and verify your accreditation status to gain access to:

  • Laviana Pharma current valuation
  • Laviana Pharma stock price
  • Available deals in Laviana Pharma and all other companies
  • Deal offering documents
  • EquityZen's proprietary data and insights, including
    • Cap tables, which include funding history by Share Class and Liquidity Preferences
    • Company Highlights
    • Business Model
    • Risk Factors
Join Now

How to invest in Laviana Pharma stock?

Accredited investors can buy pre-IPO stock in companies like Laviana Pharma through EquityZen funds. These investments are made available by existing Laviana Pharma shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.

How to sell Laviana Pharma stock?

Shareholders can sell their Laviana Pharma stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.

If I invest, how do I exit my investment?

There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.

Why choose EquityZen?

Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."